Latest On BeyondSpring Inc (BYSI):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-04-18 21:19 EST | News | BeyondSpring GAAP EPS of -$0.85 beats by $0.28, revenue of $1.35M misses by $14.16M | N/A |  |
| 2023-01-10 20:38 EST | News | BeyondSpring regains Nasdaq compliance on minimum bid price | N/A | |
| 2022-12-13 20:49 EST | News | BeyondSpring rises 18% on positive data from trial of plinabulin to prevent docetaxel-induced neutropenia in NSCLC patients | N/A | |
| 2022-11-24 03:38 EST | News | BeyondSpring gets Nasdaq's listing deficiency notice | N/A | |
| 2022-04-19 03:45 EST | News | BeyondSpring Inc.'s (BYSI) CEO Lan Huang on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-04-14 20:21 EST | News | BeyondSpring GAAP EPS of -$1.64 beats by $0.02, revenue of $1.35M misses by $7.22M | N/A | |
| 2022-04-14 20:20 EST | News | BeyondSpring Inc. 2022 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-04-14 20:20 EST | News | BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-04-13 15:07 EST | News | BeyondSpring Q4 2021 Earnings Preview | N/A | |
| 2022-02-04 01:38 EST | News | BeyondSpring, Beyond Salvage | N/A | |
| 2022-01-12 02:01 EST | News | BeyondSpring Pharmaceuticals cuts 35% of its U.S. workforce | N/A | |
| 2021-12-30 09:37 EST | News | BeyondSpring reports upcoming clinical milestones | N/A | |
| 2021-12-30 09:37 EST | News | BeyondSpring EPS misses by $0.10 | N/A | |
| 2021-12-07 07:11 EST | News | Warning: BYSI is at high risk of performing badly | N/A | |
| 2021-12-03 10:31 EST | News | BeyondSpring extends slump; analyst calls regulatory setback “somewhat surprising” | N/A | |
| 2021-12-02 14:30 EST | News | BeyondSpring downgraded at H.C. Wainwright as share slide continues | N/A | |
| 2021-12-01 18:50 EST | News | BeyondSpring plunges on FDA rejection of plinabulin combo for chemotherapy-induced neutropenia | N/A | |
| 2021-11-30 22:02 EST | News | BeyondSpring, CTI BioPharma gain ahead of FDA decision for key drugs | N/A | |
| 2021-11-19 08:49 EST | News | BeyondSpring CEO Dr. Lan Huang - Targeting Cancer (Video) | N/A | |
| 2021-11-17 13:47 EST | News | Circling Back On BeyondSpring | N/A | |
| 2021-10-22 03:43 EST | News | BeyondSpring treats first patient in mid-stage plinabulinc lung cancer study | N/A | |
| 2021-10-21 02:01 EST | News | BeyondSpring's plinabulin shows activity against lung cancer sub-type in preclinical study | N/A | |
| 2021-09-21 13:37 EST | News | Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns | N/A | |
| 2021-09-21 13:36 EST | News | BeyondSpring drops 16% despite 'positive' plinabulin/docetaxel combo data in late-stage lung cancer study | N/A | |
| 2021-09-21 13:35 EST | News | BeyondSpring posts biggest intraday loss after trial data; H.C. Wainwright cuts price target | N/A | |
| 2021-09-17 15:28 EST | News | BeyondSpring releases meta-analysis on plinabulin for neutropenia | N/A | |
| 2021-09-10 17:58 EST | News | BeyondSpring reports Q2 results | N/A | |
| 2021-09-10 17:57 EST | News | BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-09-09 21:44 EST | News | BeyondSpring Q2 2021 Earnings Preview | N/A | |
| 2021-09-09 01:23 EST | News | BeyondSpring gains as Baird sees FDA approval for its lead asset | N/A | |
| 2021-09-08 05:33 EST | News | BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk | N/A | |
| 2021-09-08 05:32 EST | News | BeyondSpring sheds over 10% recording second biggest loss for the year | N/A | |
| 2021-08-28 01:20 EST | News | Trillium, Triple-S lead weekly healthcare gainers amid acquisitions; Cassava Sciences lags | N/A | |
| 2021-08-26 09:55 EST | News | BeyondSpring inks plinabulin development and commercialization deal in Greater China | N/A | |
| 2021-08-07 15:26 EST | News | BeyondSpring leads weekly healthcare gainers; Earnings weigh on worst performers | N/A | |
| 2021-08-05 01:07 EST | News | BeyondSpring (BYSI) stock quadruples on positive plinabulin combo data in lung cancer | N/A | |
| 2021-08-05 01:05 EST | News | BeyondSpring climbs; H.C. Wainwright sets $100 target seeing dramatic shift in thesis | N/A | |
| 2021-08-01 00:07 EST | News | BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space | N/A | |
| 2021-07-20 23:12 EST | News | BeyondSpring reports plinabulin combo data in lung cancer at ASCO meeting 2021 | N/A | |
| 2021-07-20 23:06 EST | News | FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8% | N/A | |
| 2021-07-20 23:03 EST | News | Dosing underway in BeyondSpring's triple combo study of plinabulin in solid tumors | N/A | |
| 2021-07-20 23:03 EST | News | BeyondSpring (BYSI) Investor Presentation - Slideshow | N/A | |
| 2021-07-20 23:02 EST | News | BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia | N/A | |
| 2021-07-20 22:55 EST | News | BeyondSpring EPS misses by $0.04 | N/A | |
| 2021-07-20 22:54 EST | News | BeyondSpring Inc. (BYSI) CEO Dr. Lan Huang on Q1 2021 Results - Earnings Call Transcript | N/A | |
| 2021-05-02 01:21 EST | News | BeyondSpring Inc. (BYSI) CEO Dr. Lan Huang on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-05-01 05:20 EST | News | BeyondSpring Inc. 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-04-30 07:22 EST | News | BeyondSpring EPS misses by $0.17 | N/A | |
| 2021-04-06 00:10 EST | News | BeyondSpring downgraded at H.C. Wainwright despite a potential launch of Plinabulin | N/A | |
| 2021-04-01 13:18 EST | News | BeyondSpring files plinabulin + G-CSF application in U.S. and China | N/A | |
About BeyondSpring Inc (BYSI):
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.
General
- Name BeyondSpring Inc
- Symbol BYSI
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 61
- Fiscal Year EndDecember
- IPO Date2017-03-09
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.beyondspringpharma.com
View More
Valuation
- Price/Book (Most Recent Quarter) 25.09
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.50
- Return on Assets -103%
- Return on Equity -268%
- Earnings Per Share -$1.90
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 475.18 million
- EBITDA -45610000
- Analyst Target Price $33.25
- Book Value Per Share $0.79
View More
Share Statistics
- Shares Outstanding 39.14 million
- Shares Float 16.07 million
- % Held by Insiders 7155%
- % Held by Institutions 6.2%
- Shares Short 1.2 million
- Shares Short Prior Month 1.2 million
- Short Ratio 3.96
- Short % of Float 4%
- Short % of Shares Outstanding 3%
View More
Technicals
- Beta 0.61
- 52 Week High $18.67
- 52 Week Low $9.83
- 50 Day Moving Average 13.39
- 200 Day Moving Average 13.22
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
BeyondSpring Inc (BYSI) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
BeyondSpring Inc (BYSI) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-17 | $N/A | -$0.48 | -$0.54 | 11.11% |
| 2020-06-30 | 2020-09-03 | $N/A | -$0.46 | -$0.57 | 19.3% |
| 2020-03-31 | 2020-04-30 | $N/A | -$0.52 | -$0.40 | -29.19% |
| 2019-12-31 | 2019-12-31 | $N/A | -$0.52 | -$0.43 | -20.93% |
| 2019-09-30 | 2019-12-18 | $N/A | -$0.37 | -$0.30 | -23.33% |
| 2019-06-30 | 2019-07-10 | $N/A | -$0.32 | -$0.63 | 49.21% |
| 2019-03-31 | 2019-04-30 | $N/A | -$0.64 | -$0.55 | -16.36% |
| 2018-09-30 | 2018-10-23 | $N/A | -$0.54 | -$0.59 | 7.69% |
| 2018-06-30 | 2018-06-30 | $N/A | -$0.54 | -$0.60 | 10% |
| 2018-03-31 | 2018-06-21 | $N/A | -$0.61 | -$0.61 | 0.54% |
| 2017-12-31 | 2018-02-03 | $N/A | -$0.68 | -$0.62 | -9.68% |
| 2017-09-30 | 2017-11-09 | $N/A | -$0.68 | -$0.35 | -94.29% |
| 2017-06-30 | 2017-08-21 | $N/A | -$0.39 | -$0.24 | -62.5% |
| 2017-03-31 | 2017-04-28 | $N/A | -$0.21 | -$0.17 | -23.53% |
BeyondSpring Inc (BYSI) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
BeyondSpring Inc (BYSI) Chart:
BeyondSpring Inc (BYSI) News:
Below you will find a list of latest news for BeyondSpring Inc (BYSI) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
BeyondSpring Inc (BYSI) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.35 | CALL | 0 | 44 | 154.6 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.15 | CALL | 0 | 31 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0.1 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0.56 | PUT | 0 | 4 | 178.51 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 2.4 | PUT | 0 | 1 | 222.98 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 325.82 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 1.9 | CALL | 0 | 8 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 168.96 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | PUT | 0 | 0 | 189.87 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 288.34 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 361.88 | TRUE | 0 | 0 |
| 2024-07-19 | 2.5 | 0.6 | CALL | 0 | 1035 | 156.95 | FALSE | 0 | 0 |
| 2024-07-19 | 5 | 0.21 | CALL | 10 | 80 | 162.91 | FALSE | 0.21 | 0 |
| 2024-07-19 | 7.5 | 0.4 | CALL | 0 | 128 | 168.62 | FALSE | 0 | 0 |
| 2024-07-19 | 2.5 | 1.1 | PUT | 0 | 29 | 162.38 | TRUE | 0 | 0 |
| 2024-07-19 | 5 | 0 | PUT | 0 | 0 | 362.61 | TRUE | 0 | 0 |
| 2024-07-19 | 7.5 | 6.6 | PUT | 0 | 0 | 211.13 | TRUE | 0 | 0 |
| 2024-10-18 | 2.5 | 0.89 | CALL | 0 | 61 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 5 | 0.45 | CALL | 0 | 249 | 145.03 | FALSE | 0 | 0 |
| 2024-10-18 | 7.5 | 0.6 | CALL | 0 | 14 | 139.55 | FALSE | 0 | 0 |
| 2024-10-18 | 2.5 | 1 | PUT | 0 | 13 | 141.01 | TRUE | 0 | 0 |
| 2024-10-18 | 5 | 2.5 | PUT | 0 | 10 | 146.72 | TRUE | 0 | 0 |
| 2024-10-18 | 7.5 | 0 | PUT | 0 | 0 | 155.52 | TRUE | 0 | 0 |
Latest BYSI Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 200 | $1.685 |
| Jun 13, 2022 7:59 PM EST | 100 | $1.69 |
| Jun 13, 2022 7:59 PM EST | 20 | $1.68 |
| Jun 13, 2022 7:59 PM EST | 49 | $1.68 |
| Jun 13, 2022 7:59 PM EST | 100 | $1.69 |
BeyondSpring Inc (BYSI) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120014552/0001140361-20-014552-index.htm |
| 2016-07-29 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1677940/000000000016086457/0000000000-16-086457-index.htm |
| 2016-09-29 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1677940/000000000016095153/0000000000-16-095153-index.htm |
| 2016-11-15 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1677940/000000000016100905/0000000000-16-100905-index.htm |
| 2017-02-17 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1677940/000000000017005715/0000000000-17-005715-index.htm |
| 2017-03-01 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1677940/000000000017006914/0000000000-17-006914-index.htm |
| 2018-04-30 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1677940/000000000018013253/0000000000-18-013253-index.htm |
| 2018-05-14 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1677940/000000000018014826/0000000000-18-014826-index.htm |
| 2018-05-17 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1677940/000000000018015362/0000000000-18-015362-index.htm |
| 2019-10-17 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1677940/000000000019014641/0000000000-19-014641-index.htm |
| 2020-02-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1677940/000110465920013788/0001104659-20-013788-index.htm |
| 2017-03-21 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1677940/000114036117012842/0001140361-17-012842-index.htm |
| 2017-08-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036117032760/0001140361-17-032760-index.htm |
| 2017-11-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036117041664/0001140361-17-041664-index.htm |
| 2018-01-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036118003570/0001140361-18-003570-index.htm |
| 2018-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1677940/000114036118007856/0001140361-18-007856-index.htm |
| 2018-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1677940/000114036118007861/0001140361-18-007861-index.htm |
| 2018-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1677940/000114036118007867/0001140361-18-007867-index.htm |
| 2018-02-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036118009214/0001140361-18-009214-index.htm |
| 2018-03-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036118015095/0001140361-18-015095-index.htm |
| 2018-04-03 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036118016587/0001140361-18-016587-index.htm |
| 2018-04-25 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1677940/000114036118019544/0001140361-18-019544-index.htm |
| 2018-05-01 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1677940/000114036118020737/0001140361-18-020737-index.htm |
| 2018-05-16 | 20-F/A | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036118024221/0001140361-18-024221-index.htm |
| 2018-05-16 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1677940/000114036118024222/0001140361-18-024222-index.htm |
| 2018-05-29 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036118026000/0001140361-18-026000-index.htm |
| 2018-05-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036118026134/0001140361-18-026134-index.htm |
| 2018-06-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036118029411/0001140361-18-029411-index.htm |
| 2018-08-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036118034649/0001140361-18-034649-index.htm |
| 2018-10-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036118041086/0001140361-18-041086-index.htm |
| 2018-10-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036118041088/0001140361-18-041088-index.htm |
| 2019-04-30 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119008017/0001140361-19-008017-index.htm |
| 2019-05-21 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119009534/0001140361-19-009534-index.htm |
| 2019-05-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119009645/0001140361-19-009645-index.htm |
| 2019-07-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119012689/0001140361-19-012689-index.htm |
| 2019-07-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119012694/0001140361-19-012694-index.htm |
| 2019-07-16 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119013025/0001140361-19-013025-index.htm |
| 2019-07-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119013127/0001140361-19-013127-index.htm |
| 2019-07-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119013200/0001140361-19-013200-index.htm |
| 2019-09-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119016882/0001140361-19-016882-index.htm |
| 2019-10-15 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1677940/000114036119018409/0001140361-19-018409-index.htm |
| 2019-10-17 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1677940/000114036119018569/0001140361-19-018569-index.htm |
| 2019-10-25 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119018999/0001140361-19-018999-index.htm |
| 2019-10-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119019194/0001140361-19-019194-index.htm |
| 2019-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119019290/0001140361-19-019290-index.htm |
| 2019-12-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036119022785/0001140361-19-022785-index.htm |
| 2020-02-07 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120002601/0001140361-20-002601-index.htm |
| 2020-02-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120002616/0001140361-20-002616-index.htm |
| 2020-03-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120005478/0001140361-20-005478-index.htm |
| 2020-04-30 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120010310/0001140361-20-010310-index.htm |
| 2020-06-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120013595/0001140361-20-013595-index.htm |
| 2020-06-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120013782/0001140361-20-013782-index.htm |
| 2020-06-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120014183/0001140361-20-014183-index.htm |
| 2020-06-19 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120014332/0001140361-20-014332-index.htm |
| 2020-06-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120014552/0001140361-20-014552-index.htm |
| 2020-07-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120016651/0001140361-20-016651-index.htm |
| 2020-07-24 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1677940/000114036120016653/0001140361-20-016653-index.htm |
| 2020-08-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120018699/0001140361-20-018699-index.htm |
| 2020-09-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120019711/0001140361-20-019711-index.htm |
| 2020-09-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000114036120021194/0001140361-20-021194-index.htm |
| 2020-11-03 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1677940/000114036120024388/0001140361-20-024388-index.htm |
| 2019-08-02 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1677940/000114420419037320/0001144204-19-037320-index.htm |
| 2017-05-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000117184317002635/0001171843-17-002635-index.htm |
| 2020-01-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000117184320000424/0001171843-20-000424-index.htm |
| 2018-01-10 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1677940/000119312518008289/0001193125-18-008289-index.htm |
| 2020-07-27 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1677940/000138713120006774/0001387131-20-006774-index.htm |
| 2016-06-30 | DRS | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1677940/000156761916002557/0001567619-16-002557-index.htm |
| 2016-09-19 | DRS/A | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1677940/000156761916002974/0001567619-16-002974-index.htm |
| 2016-09-19 | DRSLTR | Correspondence Related to Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1677940/000156761916002975/0001567619-16-002975-index.htm |
| 2016-10-25 | DRS/A | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1677940/000156761916003106/0001567619-16-003106-index.htm |
| 2016-10-25 | DRSLTR | Correspondence Related to Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1677940/000156761916003107/0001567619-16-003107-index.htm |
| 2016-11-15 | F-1 | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1677940/000156761916003199/0001567619-16-003199-index.htm |
| 2016-11-15 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1677940/000156761916003200/0001567619-16-003200-index.htm |
| 2017-02-07 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000147/0001567619-17-000147-index.htm |
| 2017-02-28 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000344/0001567619-17-000344-index.htm |
| 2017-02-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000346/0001567619-17-000346-index.htm |
| 2017-02-28 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000354/0001567619-17-000354-index.htm |
| 2017-03-02 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000362/0001567619-17-000362-index.htm |
| 2017-03-02 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000364/0001567619-17-000364-index.htm |
| 2017-03-06 | 8-A12B | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000377/0001567619-17-000377-index.htm |
| 2017-03-06 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000380/0001567619-17-000380-index.htm |
| 2017-03-06 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000381/0001567619-17-000381-index.htm |
| 2017-03-08 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000399/0001567619-17-000399-index.htm |
| 2017-03-08 | F-1MEF | Registration statement to add securities to prior Form F-1 registration [Rule 462(b)] | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000405/0001567619-17-000405-index.htm |
| 2017-03-09 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000415/0001567619-17-000415-index.htm |
| 2017-03-13 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000429/0001567619-17-000429-index.htm |
| 2017-04-28 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1677940/000156761917000821/0001567619-17-000821-index.htm |
| 2017-05-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000156761917001088/0001567619-17-001088-index.htm |
| 2017-05-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1677940/000156761917001130/0001567619-17-001130-index.htm |
| 2019-02-20 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1677940/000156761919004948/0001567619-19-004948-index.htm |
| 2017-03-08 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1677940/999999999517000514/9999999995-17-000514-index.htm |
| 2018-05-03 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1677940/999999999518001135/9999999995-18-001135-index.htm |
| 2019-10-21 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1677940/999999999519002360/9999999995-19-002360-index.htm |
| 2017-03-08 | CERTNAS | Certification by the Nasdaq Stock Market approving securities for listing | https://www.sec.gov/Archives/edgar/data/1677940/999999999717001710/9999999997-17-001710-index.htm |